Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SCIO Scios Inc. -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (1360)	5/25/2001 6:01:24 PM
From: Robert Cohen	Read Replies (3) \| Respond to of 1477

It is most usual to relieve symptoms of shortness of breath within 1 hour and see improvement in arterial blood gases within the same time frame. There are groups of patients who are in extremes many of which will require urgent intubation and mechanical ventilation. These patients may require longer periods to improve. Frequently this group may be hypotensive requiring addtional therapeutic measures. I just don't see a need for an expensive new drug that may not be that more effective than current cheaper alternatives. Will it be used..yes. Will it become the standard of care...I doubt it. In addition since current treatment relies upon multiple drugs, testing this drug only against IV NTG does not tell the whole story. Robert